Canavan Disease Clinical Trial
Official title:
A Phase 1/2 Open-Label Study of the Safety and Clinical Activity of Gene Therapy for Canavan Disease Through Administration of an Adeno-Associated Virus (AAV) Serotype 9-Based Recombinant Vector Encoding the Human ASPA Gene
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Canavan disease is an ultra-rare, profoundly disabling and fatal disease with no approved therapy. The Sponsor is developing BBP-812, an investigational gene therapy product for systemic delivery in participants with Canavan disease. BBP-812 is a recombinant adeno-associated virus serotype 9 (rAAV9) vector engineered to deliver the aspartoacylase (ASPA) transgene under control of a ubiquitous promoter to restore ASPA expression in both neuronal and non-neuronal cell types. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00657748 -
Lithium and Acetate for Canavan Disease
|
Phase 2 | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Recruiting |
NCT04126005 -
Natural History Study of Patients With Canavan Disease
|
||
| Completed |
NCT02851563 -
A Natural History Study of Canavan Disease
|
||
| Recruiting |
NCT00724802 -
Oral Glyceryl Triacetate (GTA) in Newborns With Canavan
|
N/A | |
| Completed |
NCT01999257 -
Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent.
|
N/A | |
| Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
| Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|
||
| Recruiting |
NCT04833907 -
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
|
Phase 1/Phase 2 | |
| No longer available |
NCT05317780 -
Canavan-Single Patient IND
|